IL6 and COVID-19: In fact, the optimal results of clinical trials with tocilizumab (an IL-6 inhibitor) in patients with severe and critical COVID-19 led to its approval by the U.S. Food and Drug Administration (FDA) and its inclusion in the current Guidance for the Management of Acute COVID-19 in Children [34].